TSLPR: a new CAR in the showroom for B-ALL.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Molecularly targeted therapy and immunotherapy in leukemias.Journal of hematology & oncology · 2026
   Review
2. CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects.Biomedicines · 2023
   Review
3. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study.Cancer gene therapy · 2022
   Review
4. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Journal of immunology research · 2018
   Review
5. CAR T-cell immunotherapy: The path from the by-road to the freeway?Molecular oncology · 2015
   Review

Corrections and comments

• Comment on
  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as